Senses Disorder TRIZ Cases

Peptides targeting the Ca v β2 Tail Interacting Domain stabilize LTCC density, restoring intracellular Ca2+ homeostasis in heart failure.

An azabenzimidazole compound binds to the allosteric site of M3 muscarinic receptors to enhance signal transduction without direct orthosteric activation.

Oral green chiretta containing andrographolide reduces intraocular pressure and visual field defects across varying glaucoma types.

Hyperbaric oxygen solutions and biodegradable implants deliver elevated oxygen pressure to treat ischemic conditions and reduce hypoxic induction factor levels.

Shark-derived vNAR antibodies neutralize vascular endothelial growth factor, enabling topical treatment for neovascular eye conditions.

Selective p38 MAP kinase inhibition reduces systemic toxicity while maintaining anti-inflammatory efficacy.

N-cyclopropyl amines improve blood-brain barrier permeability and pharmacokinetic profiles for treating CNS disorders.

Convergent synthesis pathways minimize intermediate isolation, reducing purification steps and boosting overall yield for quinazoline derivatives.

Segmenting tumors by NP1, NP2, and PlexD1 receptor levels to select specific semaphorins that reduce blood vessel density.

Segmenting neuropilin receptors into distinct domains enables antibodies to selectively inhibit semaphorin binding without disrupting VEGF interactions.

Sustained-release kallikrein inhibitors reduce exudation and inflammation by targeting specific protease activity in ophthalmic disorders.

A trifluoromethyl-substituted dihydronaphthalene compound selectively activates S1P5 receptors.

A cell-free mesenchymal stem cell secretome composition delivers trophic factors to promote ocular wound healing and preserve vision.

Cyclodextrin inclusion complexes enable aqueous formulation of lipophilic agents, reducing A2E accumulation in RPE cells while minimizing systemic exposure.

Engineered antibodies remove beta-amyloid deposits to modify disease progression in Alzheimer's and ocular disorders.

A sustained-release magnesium tablet uses hydrophilic and hydrophobic delay agents to control dissolution rates.

Polymorph Form II of Icotinib maleate improves bioavailability through distinct crystal structures.

Activated amniocytes phagocytize pathological cells, reducing side effects from conventional drug therapies.

Inhibiting or stimulating Ptger3-positive neurons in the lamina terminalis reduces sodium intake by altering aversive taste tolerance.

Preservative-free rh-bFGF formulation eliminates ocular surface damage while providing sustained tear secretion relief.

Pyrimidine pyrazolyl derivatives selectively inhibit IRAK-4 and IRAK-1 to treat inflammatory diseases without compromising immune defense.

A DNA oligonucleotide selectively binds to IFN-gamma for dry eye treatment.

A therapeutic contact lens depletes zinc ions to deactivate matrix metalloproteinases in the eye.

Alpha-humulene addresses mucin deficiency by stimulating natural production to restore tear film stability and improve dry eye symptoms.

Pilocarpine ionic liquid analogs prevent epimerization to maintain structural stability and cytocompatibility.

L234F, L235E, and P331S mutations in the antibody Fc region reduce Fc ligand binding to mitigate toxicity while preserving IFNAR1 targeting.

Aromatic-cationic peptides address inadequate mitochondrial myopathy treatments by restoring skeletal muscle function and boosting ATP production.

Fluid bed granulation of pirfenidone with an intragranular glidant resolves poor powder flowability while maintaining therapeutic effectiveness.

A liposomal eye drop solution uses 0.2 micron filtration to sterilize formulations without thermal damage.

Lowering culture temperature to 30.0°C–34.0°C reduces aggregate formation while maintaining cell growth, improving protein quality and yield.

Polyoxyl lipid nanomicelles solubilize hydrophobic drugs without irritant organic solvents, maintaining stability at elevated temperatures.

Tocopherol eyedrops absorb and release aqueous components, reducing water evaporation from the eye surface to alleviate chronic dry eye symptoms.

D-aspartic acid neutralizes hydroxyl and peroxyl radicals to suppress oxidative damage in fibroblasts, replacing unstable conventional antioxidants.

Optimized lanreotide concentrations reduce viscosity, allowing injection force reduction and pain minimization via thinner needles.

6-6 fused bicyclic heteroaryl compounds inhibit LATS kinases to expand ocular and liver cell populations.

Monoclonal antibodies target IL-21 receptors to block inflammatory signaling, reducing autoimmune disease symptoms without broad immunosuppression.

Pyridin-oxadiazole compounds restore defective CFTR protein activity, addressing underlying salt transport failures in cystic fibrosis.

Using a multi-agonist panel to assess T2R phenotypic expression, improving susceptibility prediction reliability for respiratory infections.

Biparatopic polypeptides merge two binding domains to inhibit CXCR2 signaling and reduce inflammatory cell migration in chronic obstructive pulmonary disease.

PEGylated lipid nanoparticles encapsulate lipophilic agents to prevent precipitation and stinging during ocular administration.

Combining resveratrol and saffron creates a synergistic antioxidant formulation that protects retinal cells from oxidative damage.

A bicyclic heterocyclic compound with an acylamino group inhibits the enzyme 11β-HSD1.

Aprocitentan resolves fluid retention side effects while controlling resistant hypertension.

Soluble Nogo receptor-1 polypeptides bind the receptor to block inhibitory ligand interactions and promote axonal regeneration.

Peptide epitopes derived from HLA molecules activate cytotoxic T cells, reducing side effects on normal tissues while targeting tumors.

Topical mineralocorticoid receptor antagonists maintain epidermal thickness during glucocorticoid therapy.